- Home
- USB vs BMY Comparison
USB vs BMY Comparison
Compare USB & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USB | BMY |
|---|---|---|
| Founded | 1863 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.4B | 113.5B |
| IPO Year | 2009 | 2006 |
Fundamental Metrics
Financial Performance| Metric | USB | BMY |
|---|---|---|
| Price | $62.01 | $67.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 15 |
| Target Price | $60.28 | ★ $61.73 |
| AVG Volume (30 Days) | 6.0M | ★ 11.8M |
| Earning Date | 04-16-2026 | 04-30-2026 |
| Dividend Yield | 3.70% | ★ 4.38% |
| EPS Growth | 21.90 | ★ 178.46 |
| EPS | 2.53 | ★ 2.93 |
| Revenue | $28,656,000,000.00 | ★ $48,194,000,000.00 |
| Revenue This Year | $16.09 | N/A |
| Revenue Next Year | $5.36 | N/A |
| P/E Ratio | $24.48 | ★ $22.37 |
| Revenue Growth | ★ 4.37 | N/A |
| 52 Week Low | $45.02 | $42.52 |
| 52 Week High | $66.08 | $68.64 |
Technical Indicators
Market Signals| Indicator | USB | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 41.43 | 63.92 |
| Support Level | $52.92 | $56.46 |
| Resistance Level | $64.76 | $68.10 |
| Average True Range (ATR) | 1.06 | 1.59 |
| MACD | -0.42 | 0.03 |
| Stochastic Oscillator | 12.35 | 75.62 |
Price Performance
Historical ComparisonAbout USB U.S. Bancorp
With assets of around $700 billion, U.S. Bancorp is one of the largest regional banks in the US with its footprint in 26 states. The bank's branch network is mostly in Midwestern and Western markets. U.S. Bancorp has a comprehensive product set, with offerings in retail and commercial banking, credit cards, mortgages, payment services, trust, wealth, and capital market services.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.